Joint research and a capital and business alliance with SanBio aimed at the appropriate use, broader adoption and stable distribution of regenerative cell medicines

「In September 2018, in order to respond as quickly as possible to the future adoption of regenerative cell therapies, five companies, including our company, decided to conduct joint research into the appropriate use and adoption of regenerative cell therapies and methods for ensuring stable distribution. To establish a strong cooperative framework for this joint research, our company entered into a capital and business alliance with SanBio Company Limited.」

「In September 2018, in order to respond as quickly as possible to the future adoption of regenerative cell therapies, five companies, including our company—SanBio Company Limited (securities code 4592, Tokyo Stock Exchange Mothers, Representative Director and President Mori Keita (森 敬太), head office: Chuo-ku, Tokyo), ケアネット株式会社 (securities code 2150, Tokyo Stock Exchange Mothers, Representative Director and President Fujii Katsuhiro (藤井 勝博), head office: Chiyoda-ku, Tokyo), 株式会社メディカルインキュベータジャパン (Representative Director and President Katsura Jun (桂 淳), head office: Minato-ku, Tokyo), and 株式会社アステム (Representative Director and President Yoshimura Tsugio (吉村 次生), head office: Oita City, Oita)—decided to conduct joint research into the appropriate use and adoption of regenerative cell therapies and methods for ensuring stable distribution. To establish a strong cooperative framework for this joint research, our company entered into a capital and business alliance with SanBio Company Limited.」

「In September 2018, in order to respond as quickly as possible to the future adoption of regenerative cell therapies, five companies, including our company—SanBio Company Limited (code 4592, Tokyo Stock Exchange Mothers, Representative Director and President Mori Keita (森 敬太), head office: Chuo-ku, Tokyo; hereinafter, “SanBio”), ケアネット株式会社 (code 2150, Tokyo Stock Exchange Mothers, Representative Director and President Fujii Katsuhiro (藤井 勝博), head office: Chiyoda-ku, Tokyo), 株式会社メディカルインキュベータジャパン (Representative Director and President Katsura Jun (桂 淳), head office: Minato-ku, Tokyo), and 株式会社アステム (Representative Director and President Yoshimura Tsugio (吉村 次生), head office: Oita City, Oita)—decided to conduct joint research into the appropriate use and adoption of regenerative cell therapies and methods for ensuring stable distribution. To establish a strong cooperative framework for this joint research, our company entered into a capital and business alliance with SanBio Company Limited.」